Yuhan
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Yuhan makes prescription and over-the-counter medicines, drugs used to treat everyday and chronic conditions, as well as other health-care products supplied to patients and healthcare providers in Korea.
The company is listed on KOSPI, Korea's main stock exchange. The filing covers a broad range of business activities including product development, raw-material sourcing, and active research and development, suggesting a diversified pharmaceutical operation rather than reliance on a single product line.
Summary is AI-generated and may contain errors · figures from DART filings
Yuhan in five facts
What does Yuhan do?
Yuhan makes prescription and over-the-counter medicines, drugs used to treat everyday and chronic conditions, as well as other health-care products supplied to patients and healthcare providers in Korea.
Where is Yuhan listed and in which sector?
Yuhan (Korean name: 유한양행) trades under KRX code 000100 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Yuhan?
Its market capitalisation was US$4.8B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Yuhan's latest annual revenue and operating profit?
For fiscal year 2025, Yuhan reported revenue of US$1.7B, operating profit of US$78.8M and net income of US$139.9M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 5.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 2
- Supply contract signed
Yuhan disclosed a supply contract, worth US$57.6M, about 3.6% of its recent annual revenue, running through Jul 2028.
Supply contract · Sep 15 - Report on securities held by executives/major shareholdersSep 9
- Investor relations (IR) meeting (notice)Sep 8
- Supply contract signed
Yuhan disclosed a supply contract, worth US$95.5M, about 6% of its recent annual revenue, running through May 2028.
Supply contract · Sep 1 - Operating results (preliminary) (fair disclosure)
Yuhan filed provisional (unaudited) separate results for Q2 2026: revenue of US$432M (+10.4% year on year), operating profit of US$43.3M (+34.7% year on year) and net income of US$33.5M (+22.1% year on year).
Earnings · Jul 30 - Supply contract signed
Yuhan disclosed a supply contract, worth US$140M, about 9.61% of its recent annual revenue, running through Dec 2027.
Supply contract · May 20 - [Amended] Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · May 11 · 4 versions
- Supply contract signed
Yuhan disclosed a supply contract with BridgeBio Pharma, Inc., worth US$38.8M, about 2.56% of its recent annual revenue, running through Mar 2028.
Supply contract · May 6 - Operating results (preliminary) (fair disclosure)
Yuhan filed provisional (unaudited) separate results for Q1 2026: revenue of US$346M (+8.6% year on year), operating profit of US$5.99M (+2.1% year on year) and net income of US$25.3M (−5% year on year).
Earnings · Apr 30 - Cash/in-kind dividend decision
Yuhan declared a cash dividend of US$0.41 per share.
Dividend · Feb 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Yuhan reported consolidated results for FY2025: revenue of US$1.5B (+5.7% year on year), operating profit of US$71.7M (+90.2% year on year) and net income of US$127M (+235.9% year on year).
Earnings · Feb 11